NEW YORK, Dec. 17 - Functional genomics and proteomics technology developer Agilix has closed a Series B financing round worth $20.8 million, the firm said on Monday.
Â
Burrill & Company, Hambrecht & Quist Capital Management, Stephens Group, Wheatley MedTech Partners, and BioVeda participated in the round, which also included a reinvestment by Series A investor ATP Capital.
Â
The capital will help Agilix, of New Haven, Conn., commercialize and ramp up production of its FAAST whole-transcriptome analysis system and its ZeptoLabeling technology for proteomic-based drug-discovery.
Â
"We appreciate the industry's enthusiasm for our technologies and we look forward to scaling our production facilities to serve our discovery partners," Martin J. Mattessich, president & CEO of Agilix, said in a statement. "This is a fundamental change in the way companies approach both gene and protein expression profiling. These technologies will allow Agilix and our partners to study new genes, pathways, and toxicology profiles in any disease system and in any model organism."